Responding to the new energy bill announced in the Queen's Speech, Mike Hobday, Head of Campaigns at Macmillan Cancer Support said: 'Whilst the mandatory support from energy companies will help some vulnerable people struggling with their fuel bills, it is vital that cancer patients are not left out in the cold...

Two studies reveal that smokers may have a significantly lower risk of developing lung cancer and colorectal cancer with the drug metformin, which is commonly prescribed for diabetes type 2 treatment, the medical journal Cancer Prevention Research informs...

Pawlenty's Order Pure Politicking The Bemidji (Minn.) Pioneer The move can be explained in no other way than in being a totally partisan decision, intended to shore up his conservatism in what will be a 2012 battle of who is more conservative to wear the Republican mantle for president (9/1)...

Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat. Around 60 patients with advanced pancreatic cancer will be recruited for the first Phase I/IIclinical trial of a drug called MK-0752** in this disease...

Scientists are reporting new evidence that the fat tissue in those spare tires and lower belly pooches - far from being a dormant storage depot for surplus calories - is an active organ that sends chemical signals to other parts of the body, perhaps increasing the risk of heart attacks, cancer, and other diseases...

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced that the first CyberKnife VSI System to be installed in Europe was placed at the Leon-Berard Cancer Multidisciplinary Center (CLB) in Lyon, France. The CyberKnife VSI System is the newest addition to the CyberKnife product family...

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing...

Gulf Coast Cancer Treatment Center, the area's only American College of Radiology-accredited radiation oncology center, introduces the Elekta Synergy system. The new technology will be showcased at the center's Open House on Thursday, September 16, 2010 from 1 p.m. to 7 p.m. Gulf Coast Cancer Treatment Center (GCCTC) is located at 2100 State Avenue in Panama City. Radiation oncologists Dr. D.B...

Radiation Oncology Services of America, Inc. (ROSA), a subsidiary of Ambulatory Services of America, Inc. (ASA), announced that it has entered into an agreement with the Department of Radiation Oncology at the Washington University in St. Louis School of Medicine to embark on a Cooperative Quality Assurance Project...

Michael Douglas told a US television audience on Tuesday night that he has been diagnosed with and is receiving treatment for stage four throat cancer. Speaking on David Letterman's "Late Show" to promote the release of his new film "Wall Street: Money Never Sleeps", the 65- year old American actor and producer said his doctors had told him he has an 80 per cent chance of survival...

Detection of circulating and disseminated tumor cells in blood is a promising methodology to diagnose cancer dissemination or to follow up cancer patients during therapy. Today, the detection analyses of these cells are performed in medical laboratories requiring labor intensive, expensive and time-consuming sample processing and cell isolation steps...

Using readily available computer programs, researchers have developed a system to identify genes that will be useful in the classification of breast cancer. The algorithm, described in BioMed Central's open access Journal of Experimental & Clinical Cancer Research will enable researchers to quickly generate valuable gene signatures without specialized software or extensive bioinformatics training...

Two new groundbreaking scientific papers by researchers at UC Santa Barbara demonstrate the synthesis of nanosize biological particles with the potential to fight cancer and other illnesses. The studies introduce new approaches that are considered "green" nanobiotechnology because they use no artificial compounds...

A "game-changing" technique using near infrared light enables scientists to look deeper into the guts of cells, potentially opening up a new frontier in the fights against cancer and many other diseases. University of Central Florida chemists, led by Professor Kevin Belfield, used near infrared light and fluorescent dye to take pictures of cells and tumors deep within tissue...

Survival rates overall for childhood cancer are almost 80 percent a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading cause of death due to disease among U.S. children older than 1 year of age. While September is Childhood Cancer Awareness Month nationwide, at St...

Harris Interactive/HealthDay poll finds 30 percent of those overweight think they're normal size

Harris Interactive/HealthDay poll finds 30 percent of those overweight think they're normal size

Study finds long-distance friends less likely to sway behavior than close-knit social networks

Eisai Inc. announced today that it has received notification from the U.S...

People who consume a variety of vegetables tend to have a lower risk of developing lung cancer compared to those who don't, according to a study published in the medical journal Cancer Epidemiology, Biomarkers & Prevention, a publication of the American Association for Cancer Research...

A common mineral may provide protection against bladder cancer. According to results of a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, selenium intake is associated with decreased risk of bladder cancer...

Women with the inherited mutations of the BRCA1 or BRCA2 genes who had preventive (prophylactic) breast removal (mastectomy) or the removal of the fallopian tubes and ovaries (salpingo-oophorectomy) were found to have a significantly lower risk of developing ovarian and breast cancers, says a study published in JAMA (Journal of the American Medical Association), September 1st issue...

Related Articles

Using the illness intrusiveness ratings scale to understand health-related quality of life in chronic disease.

J Psychosom Res. 2010 Jun;68(6):591-602

Authors: Devins GM

OBJECTIVE: Illness intrusiveness is a common, underlying determinant of quality of life in people affected by chronic disease. Illness intrusiveness results from disease- and treatment-induced disruptions to lifestyles, activities, and interests (i.e., interference with psychologically meaningful activity). This paper introduces the Illness Intrusiveness Ratings Scale (IIRS), a 13-item, self-report instrument. The IIRS can be scored to generate a total score or three subscale scores: relationships and personal development, intimacy, and instrumental. In addition to describing the IIRS, the paper presents the theoretical framework in which it is anchored, reviews the evidence, and reports psychometric properties. METHODS: Qualitative literature review. RESULTS: Findings support the IIRS's reliability (internal consistency and test-retest), validity (construct, criterion-related, and discriminant), sensitivity to change, and factorial invariance across numerous chronic-disease groups. The paper reports IIRS reliability coefficients and normative statistics for 36 chronic, medical and psychiatric patient populations. CONCLUSION: The IIRS taps the extent to which disease- and treatment-related factors interfere with psychologically meaningful activity among people affected by chronic disease. It provides a valid, reliable measure that is easy to administer and unequivocally interpretable rendering it suitable for research designed to estimate the psychosocial impact of chronic disease and to document (and compare) the effectiveness of therapeutic interventions.

PMID: 20488277 [PubMed - indexed for MEDLINE]

Related Articles

Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.

J Gastroenterol Hepatol. 2010 Apr;25(4):657-63

Authors:

Among approximately 650,000 people who die from hepatocellular carcinoma (HCC) each year, at least two-thirds live in Asia. Efforts to improve early diagnosis and treatment have not yet impacted mortality. An Asia-Pacific Working Party convened in Hong Kong in June 2008 to consider ways to prevent HCC in this region. Separate reviews have summarized epidemiology of HCC, preventive approaches related to hepatitis B virus (HBV), hepatitis C virus (HCV) and non-viral liver diseases, and the role of surveillance to detect HCC at a curative stage. We now present Consensus Statements from these deliberations and reviews. As chronic hepatitis B is the most common cause of HCC in Asia, effective hepatitis B vaccination programs are the most important strategy to reduce HCC incidence. Prevention of HCV by screening blood donors, universal precautions against blood contamination in health-care settings and reducing HCV transmission from injection drug use are also vital. There is strong evidence that effective antiviral therapy to control HBV infection or eradicate HCV substantially reduces (but does not abolish) HCC risk. With hemochromatosis, family screening, early diagnosis and correcting iron overload to prevent liver fibrosis prevents HCC. There is currently insufficient evidence to give firm recommendations on alcohol, obesity/metabolic risk factors and other liver diseases. HCC surveillance for high-risk groups is recommended in individual cases but cost-effectiveness is not as high as infant hepatitis B vaccination and screening blood for HCV. Widespread application of HCC surveillance in Asia-Pacific countries depends on economic factors and health-care priorities.

PMID: 20492323 [PubMed - indexed for MEDLINE]

Related Articles

Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement.

Acupunct Med. 2010 Jun;28(2):83-93

Authors: MacPherson H, Altman DG, Hammerschlag R, Li Y, Wu T, White A, Moher D,

The STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) were published in five journals in 2001 and 2002. These guidelines, in the form of a checklist and explanations for use by authors and journal editors, were designed to improve reporting of acupuncture trials, particularly the interventions, thereby facilitating their interpretation and replication. Subsequent reviews of the application and impact of STRICTA have highlighted the value of STRICTA as well as scope for improvements and revision. To manage the revision process a collaboration between the STRICTA Group, the CONSORT Group and the Chinese Cochrane Centre was developed in 2008. An expert panel with 47 participants was convened that provided electronic feedback on a revised draft of the checklist. At a subsequent face-to-face meeting in Freiburg, a group of 21 participants further revised the STRICTA checklist and planned dissemination. The new STRICTA checklist, which is an official extension of CONSORT, includes 6 items and 17 subitems. These set out reporting guidelines for the acupuncture rationale, the details of needling, the treatment regimen, other components of treatment, the practitioner background and the control or comparator interventions. In addition, and as part of this revision process, the explanations for each item have been elaborated, and examples of good reporting for each item are provided. In addition, the word 'controlled' in STRICTA is replaced by 'clinical', to indicate that STRICTA is applicable to a broad range of clinical evaluation designs, including uncontrolled outcome studies and case reports. It is intended that the revised STRICTA checklist, in conjunction with both the main CONSORT statement and extension for non-pharmacological treatment, will raise the quality of reporting of clinical trials of acupuncture.

PMID: 20615861 [PubMed - indexed for MEDLINE]

Related Articles

Is systemic anti-cancer therapy neurotoxic? Does chemo brain exist? And should we rename it?

Adv Exp Med Biol. 2010;678:86-95

Authors: Taillibert S

The existence of chemo brain has become almost universally accepted, although many details of the concept are controversial. Data about the different types of cognitive impairment and their duration are not always consistent in the literature. We still do not know which cytotoxic agents are responsible, which characteristics make patients vulnerableand which biologic mechanisms are involved. This chapter reviews the recent literature and provides an actualized definition of chemo brain, including recent functional imaging data and discusses its controversial aspects. Potential underlying mechanisms and their future possible clinical applications in the prevention and treatment of chemo brain are also discussed. These issues are of clinical importance given the prevalence of breast carcinoma, the increased use of chemotherapy as adjuvant therapy, the increasing use of more aggressive dosing schedules and the increasing survival rates. Better-designed future trials should lead to a better definition and understanding of chemo brain and to future therapies.

PMID: 20738010 [PubMed - in process]

Related Articles

Impact of childhood cancer on parents' relationships: an integrative review.

J Nurs Scholarsh. 2010 Sep 1;42(3):250-61

Authors: da Silva FM, Jacob E, Nascimento LC

Purpose: The diagnosis of cancer and the treatment decisions associated with it may cause uncertainty, stress, and anxiety among parents. Emotional tensions can affect parents' relationships during the trajectory of the child's cancer illness. We conducted an integrative review to examine the evidence related to the effects of childhood cancer on parents' relationships. Methods: An integrative literature search of studies published between 1997 and 2009 was conducted in the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Psychology Information (PsycINFO), PubMed, Scopus, CUIDEN, and Latin American and Caribbean Health Science Literature (LILACS). The key words used were neoplasms, child, marriage, spouses, family relations, and nursing. Articles were reviewed if the (a) topic addressed parents' relationships during childhood cancer; (b) participants were mothers, fathers, or both; (c) design was either qualitative or quantitative; (d) language was English, Portuguese, or Spanish; (e) date of publication was between January 1997 and October 2009; and (f) abstract was available. Results: Fourteen articles met the search criteria and were reviewed using Cooper's framework for integrative reviews. Four themes emerged: (a) changes in the parents' relationship during the trajectory of the child's illness; (b) difficulty in communication between couples; (c) gender differences in parental stress and coping; and (d) role changes. Conclusions and Implications: Findings revealed positive and negative changes in parents' relationships, communication, stress, and roles. Nurses need to assess the impact of cancer diagnosis and treatments on parent relationships, offer support and encouragement, and allow expression of feelings. Future research is needed to develop and test interventions that increase parents' potentials and strengthen relationships during the challenging trajectory of their children's cancer and treatment. Clinical Relevance: The multiple sources of stress and uncertainty associated with a child's cancer diagnosis and treatment affect parents' relationships. Difficulties in communication appear frequently in parents' relationship. Our findings may guide healthcare professionals in identifying parents at risk for developing conflicts, communication problems, and lack of alignment between parents that could interfere with providing optimal care for their child with cancer. Healthcare professionals may promote dialogue and encourage parents to express their feelings, seek mutual support, and establish a partnership in dealing with the child's illness.

PMID: 20738735 [PubMed - in process]

Related Articles

Fine-tuning the criteria for strip biopsy and endoscopic submucosal dissection improves the outcome of early gastric carcinoma treatment.

J Gastroenterol Hepatol. 2010 Sep;25(9):1514-7

Authors: Nishikawa J, Satake M, Hamabe K, Fukagawa Y, Shirai Y, Kiyotoki S, Saito M, Okamoto T, Sakaida I

Abstract Background and Aim: Strip biopsy and endoscopic submucosal dissection (ESD) have been developed as a local treatment for early gastric cancer (EGC). However, the lesion criteria for the use of ESD, rather than strip biopsy, remain to be elucidated. Methods: On the basis of reviews of literature and our observations concerning the outcome of strip biopsy, we set the criteria for selecting strip biopsy and ESD as follows. The indications for strip biopsy were lesions less than 10 mm in size and located in the anterior wall or greater curvature of the lower and middle stomach. ESD was indicated for all other lesions. The validity of the criteria was then analyzed prospectively in 156 patients. The rate of en bloc R0 resection and local recurrence were evaluated. Results: Subsequently, 156 lesions were divided according to the criteria and were endoscopically resected by strip biopsy (n = 13) or ESD (n = 143). The en bloc R0 resection rates for the whole group and the strip biopsy and ESD groups was 93.5% (146/156), 92.3% (12/13), and 93.7% (134/143), respectively. None of the patients had suffered from local recurrence in either the strip biopsy or ESD groups. Conclusion: The validity of our criteria for selecting strip biopsy and ESD was verified. Our criteria exploit the advantages of both procedures and obtain better endoscopic therapy outcomes for EGC.

PMID: 20796148 [PubMed - in process]

Related Articles

Recent progress in nanotechnology for cancer therapy.

Chin J Cancer. 2010 Sep;29(9):775-80

Authors: Tang MF, Lei L, Guo SR, Huang WL

The application of nanotechnology significantly benefits clinical practice in cancer diagnosis, treatment, and management. Especially, nanotechnology offers a promise for the targeted delivery of drugs, genes, and proteins to tumor tissues and therefore alleviating the toxicity of anticancer agents in healthy tissues. This article reviews current nanotechnology platforms for anticancer drug delivery, including polymeric nanoparticles, liposomes, dendrimers, nanoshells, carbon nanotubes, superparamagnetic nanoparticles, and nucleic acid-based nanoparticles [DNA, RNA interference (RNAi), and antisense oligonucleotide (ASO)] as well as nanotechnologies for combination therapeutic strategies, for example, nanotechnologies combined with multidrug-resistance modulator, ultrasound, hyperthermia, or photodynamic therapy. This review raises awareness of the advantages and challenges for the application of these therapeutic nanotechnologies, in light of some recent advances in nanotechnologic drug delivery and cancer therapy.

PMID: 20800018 [PubMed - in process]

Related Articles

Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options.

Cancer Treat Rev. 2010 Aug 25;

Authors: Faloppi L, Scartozzi M, Maccaroni E, Di Pietro Paolo M, Berardi R, Del Prete M, Cascinu S

Hepatocellular carcinoma (hepatocellular carcinoma, HCC) is the commonest primary liver cancer (80-90%) and represents the leading cause of cancer-related death, after lung and stomach cancer. The process of neoplastic transformation proceeds through the accumulation of mutations in the genes governing cell proliferation and apoptosis. It is currently difficult to determine the natural history of patients with untreated early-stage HCC, since most with early-stage tumor patients undergoes curative therapy. Survival rates at 3years is 65% in patients with Child-Pugh A, and single untreated lesion. This proportion increases to 70% at 5years after radical treatment. In patients included in randomized controlled clinical trials with advanced disease, survival at 1 and 2years is respectively 72% and 50%. Surgery is the only potentially curative treatment for HCC. In carefully selected patients, resection and transplantation in fact, allow a 5years survival from 60% to 70%. Unfortunately most patients in Western countries present with an intermediate or advanced HCC at diagnosis with the consequent inability to use curative treatments. These patients are therefore candidates to palliative therapies that include arterial embolization and chemoembolization and systemic treatments including chemotherapy, immunotherapy and hormonal therapy. Only recently the molecular targeted drug, Sorafenib, has been introduced among the therapeutic options for these patients.

PMID: 20800360 [PubMed - as supplied by publisher]